These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 14984818

  • 1. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
    Sin DD, Golmohammadi K, Jacobs P.
    Am J Med; 2004 Mar 01; 116(5):325-31. PubMed ID: 14984818
    [Abstract] [Full Text] [Related]

  • 2. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM, Levy AR, Spencer MD, Hurley JS, Frost FJ, Mapel DW, Briggs AH.
    Respir Med; 2005 Dec 01; 99(12):1534-45. PubMed ID: 16291076
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease.
    Lee TA, Weiss KB, Sullivan SD.
    Am J Med; 2004 Oct 15; 117(8):618; author reply 618-9. PubMed ID: 15465515
    [No Abstract] [Full Text] [Related]

  • 4. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease.
    Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J.
    Thorax; 2005 Dec 15; 60(12):992-7. PubMed ID: 16227327
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 15; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
    Respir Med; 2009 Jan 15; 103(1):12-21. PubMed ID: 19010652
    [Abstract] [Full Text] [Related]

  • 7. The role of corticosteroids in chronic obstructive pulmonary disease.
    Calverley PM.
    Semin Respir Crit Care Med; 2005 Apr 15; 26(2):235-45. PubMed ID: 16088440
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM.
    Thorax; 2008 Nov 15; 63(11):962-7. PubMed ID: 18621985
    [Abstract] [Full Text] [Related]

  • 9. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct 15; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 10. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
    Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL.
    Value Health; 2011 Dec 15; 14(8):1039-47. PubMed ID: 22152172
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL, Baker EL, Coleman CI.
    Pharmacotherapy; 2009 Aug 15; 29(8):891-905. PubMed ID: 19637942
    [Abstract] [Full Text] [Related]

  • 12. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug 15; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 13. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease.
    Pujades-Rodríguez M, Smith CJ, Hubbard RB.
    QJM; 2007 Aug 15; 100(8):509-17. PubMed ID: 17609226
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease.
    van der Palen J, Monninkhof E, van der Valk P, Sullivan SD, Veenstra DL.
    Thorax; 2006 Jan 15; 61(1):29-33. PubMed ID: 16244087
    [Abstract] [Full Text] [Related]

  • 15. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH.
    Respirology; 2008 Sep 15; 13(5):689-94. PubMed ID: 18513247
    [Abstract] [Full Text] [Related]

  • 16. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M, Biddle AK, Stearns SC.
    Clin Ther; 2008 Sep 15; 30 Spec No():1003-16. PubMed ID: 18640475
    [Abstract] [Full Text] [Related]

  • 17. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
    Sin DD, Man SF.
    Curr Opin Pulm Med; 2007 Mar 15; 13(2):90-7. PubMed ID: 17255798
    [Abstract] [Full Text] [Related]

  • 18. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K, Targowski T, From S.
    Pol Merkur Lekarski; 2009 Mar 15; 26(153):208-14. PubMed ID: 19388534
    [Abstract] [Full Text] [Related]

  • 19. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
    den Otter JJ, van Schayck CP, Folgering HT, van den Boom G, Akkermans RP, van Weel C.
    Eur J Gen Pract; 2007 Mar 15; 13(2):89-91. PubMed ID: 17534745
    [Abstract] [Full Text] [Related]

  • 20. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.
    Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW, Vestbo J, TOwards a Revolution in COPD Health (TORCH) investigators.
    Eur Respir J; 2010 Mar 15; 35(3):532-9. PubMed ID: 19717476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.